The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback